



UNIVERSITI PUTRA MALAYSIA

**EXPRESSION OF TUMOUR-ASSOCIATED ANTIGENS AND
CHARACTERISTICS OF T CELL RESPONSES IN BREAST
CARCINOMA**

LEONG PO01 PO01

FPSK(M) 2005 8

**EXPRESSION OF TUMOUR-ASSOCIATED ANTIGENS AND
CHARACTERISTICS OF T CELL RESPONSES IN BREAST CARCINOMA**

LEONG POOI POOI

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia
in Fulfilment of Requirements for the Degree of Master of Science**

March 2005



Specially dedicated to,

My mother, husband, sister and brother

For their love, understanding, encouragement and patience

Good luck to you all.

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment
of the requirements for degree of Master of Science

March 2005

**EXPRESSION OF TUMOUR-ASSOCIATED ANTIGENS AND
CHARACTERISTIC OF T CELL RESPONSES IN BREAST CARCINOMA**

By

LEONG POOI POOI

March 2005

Chairman : Professor Seow Heng Fong, PhD

Faculty : Medicine and Health Sciences

Breast cancer is the most common cancer among women in Malaysia. The standard conventional clinical management procedures use chemotherapy, radiotherapy and mastectomy. In the past decade, intense research towards the use of T-cell based immunotherapy as a treatment alternative has been made. The goals of our study are first to identify some of the tumour-associated antigens present in our tumour specimens from patients with infiltrating ductal carcinoma (IDC) of the breast, followed by antigenic peptide selection in order to develop an *in vitro* T-cell based cytotoxicity assay. At the same time, we also identified immunophenotypes of the tumour infiltrating lymphocytes (TILs) in the breast tumours. Isolated peripheral blood mononuclear cells (PBMCs) from patients with IDC were specifically stimulated with three combinations of cytokines and antibodies that were specific to the co-stimulatory molecule and HLA-A02 restricted antigen-specific peptides. Stimulated PBMCs were then used as effector cells in cytotoxicity assay using calcein-AM in which the MCF-7 breast adenocarcinoma cell line served as the target cells. Phenotypic investigation of tumour cell suspension was carried out by using specific lymphocyte cell differentiation markers. By using paraffin-embedded breast

tissues ($n=49$), immunohistochemistry studies showed significant expression of survivin (80.1%, $p<0.001$), cytoplasmic MUC-1 (38.3%, $p<0.05$) and membranous MUC-1 (63.8%, $p<0.001$) in the tumour area as compared to the apparently normal adjacent tissues. These results provided a guide for antigenic peptide selection for stimulating the T cells from the blood of the patients. Together in the presence of rIL-2 and rIL-7, 4 out of 9 peripheral blood mononuclear cells (PBMCs) from the patients responded to either survivin-derived peptide (S2) or Her2/neu specific peptide (H2) in a HLA-A02 restricted manner in order to produce sufficient amounts of effector cells for the subsequent cytotoxic assay. As effector/target (E/T) ratio increased, cytolytic activity of the effector cells became more efficient. For immunophenotypic analysis, CD8+ TILs at $23.4 \pm 2.1\%$ was found to be the major population in TILs and the presence of its effector counterpart, CD8+CD28+ TILs significantly correlated with low incidence of metastasis ($p<0.05$). At the same time, we noticed the predominance of CD4+CD25+ regulatory T cells (Treg) at $55.9 \pm 3.9\%$ in the Treg pool and its presence was significantly found in post-menopausal patients ($p<0.05$). In conclusion, survivin and MUC-1 (cytoplasmic and membranous) were over-expressed in breast cancer tissues. Further investigations are needed to determine the reasons as to why only a portion of PBMCs from the patients (4/9) responded to the specific peptide-based stimulation and showed effective cytolytic activity towards the target breast adenocarcinoma MCF-7 cell line. It is possible that other cytokine cocktails are needed to enhance the cytolytic property of the PBMCs. We also found that infiltration of effector TILs, CD8+CD28+, significantly reduced the metastatic event. Lastly, we noted that older women (≥ 50 years old) tend to possess higher amount of CD4+CD25+ Treg in TILs as compared to the younger patients (< 50 years old). The higher CD4+CD5+ Treg

in TILs may implicate poor disease outcome in older patients. We proposed that these Treg cells contribute to tumour escape mechanism.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Sarjana Sains

**TINDAK BALAS SEL T TERHADAP ANTIGEN YANG BERKAITAN
DENGAN KANSER PAYU DARA**

Oleh

LEONG POOI POOI

March 2005

Pengerusi : Profesor Seow Heng Fong, PhD

Fakulti : Perubatan dan Sains Kesihatan

Barah payudara merupakan kanser yang paling umum di kalangan wanita di Malaysia. Kaedah-kaedah perubatan klinikal yang biasa digunakan adalah kimiaterapi, radioterapi dan pembedahan. Dalam dekad yang lalu, banyak penyelidikan terhadap penggunaan imunoterapi sebagai kaedah perubatan alternatif telah dijalankan. Tujuan kajian ini adalah, pertama, untuk mengenalpasti beberapa antigen yang berkaitan dengan kanser (TAA) dalam specimen-specimen pesakit yang mengalami penyebaran sel-sel kanser ke salur duktur payudara (IDC), dan kedua, untuk memilih peptid antigen agar esej sitotoksik sel T dapat dilaksanakan. Pada masa yang sama, kami juga mengenalpasti imunofinotip dalam sel-sel limfosit yang tersebar dalam kanser payudara (TILs). Sel-sel mononuklear periperal darah (PBMC) yang diasingkan dari pesakit yang mengalami penyebaran sel –sel kanser ke salur duktur payudara telah dirangsangkan dengan menggunakan kombinasi sitokin dan antibodi yang spesifik terhadap perangsangan berpandu dan peptid spesifik terhadap antigen terhad HLA-A02. PBMC yang terangsang digunakan sebagai sel efektor dalam esej sitotoksik calcein-AM di mana sel kultur

adenokarsinoma payudara MCF-7 digunakan sebagai sel target. Penyelidikan finotip terhadap sel-sel limfosit yang tersebar dalam kanser payudara dijalankan dengan menggunakan sel-sel kanser yang telah dicerai oleh enzim dan tanda-tanda perbezaan sel limfosit yang spesifik. Dalam tisu kanser payudara yang berparafin ($n=49$), kajian imunohistokimia mempaparkan ekspresi yang nyata terhadap survivin (80%, $P<0.001$), MUC-1 di sitoplasma (38.3%, $P<0.05$) and MUC-1 di membran (63.8%, $P<0.001$) di dalam kawasan sel-sel kanser berbanding dengan sel-sel normal yang bersebelahan. Keputusan ini memberi panduan dalam pemilihan antigen peptid untuk merangsang sel-sel T limfosit daripada darah pesakit tersebut. Dengan kehadiran rIL-2 dan rIL-7, empat daripada sembilan pesakit mempunyai sel-sel mononuklear periperal darah bertindakbalas terhadap peptide survivin atau peptid spesifik Her2/neu dalam keadaan HLA-A02 dihadkan agar dapat menghasilkan sel-sel efektor yang cukup untuk esei sitotoksik yang seterusnya. Apabila ratio efector/target (E/T) meningkat, sel efektor semakin cekap menjalankan aktiviti sitolisis. Dalam imunofenotip analisa, sebanyak $23.4 \pm 2.1\%$ CD8+TILs merupakan kumpulan yang terbesar dalam TILs dan, dengan nyata sekali, kehadiran sel efektor CD8+CD28+TILs berkait rapat dengan insiden metastasis yang rendah ($P<0.05$). Pada masa yang sama, kami mendapati sel CD4+CD25+regulasi T (Treg) mendominasi kumpulan Treg dengan sebanayak $55.9 \pm 3.9\%$ dan kehadirannya hanya nyata dalam pesakit lebih tua (≥ 50 tahun) ($p<0.05$). Sebagai kesimpulan, survivin dan MUC-1 (dalam sitoplasma dan pada membran) adalah terlebih ekspres dalam tisu kanser payudara. Penyelidikan yang lebih memdalam harus dilakukan untuk mengetahui sebab-sebab kenapa hanya sebahagian daripada pesakit (4/9) bertindakbalas terhadap rangsangan spesifik peptid dan menonjolkan aktiviti sitolisis yang berkesan terhadap sel kultur adenokarsinoma payudara MCF-7.

Campuran beberapa sitokin mungkin akan meningkatkan aktiviti sitolisis PBMCs terhadap sel kanser. Kami juga mendapati sel efektor CD8+CD28+TILs berkesan mengurangkan insiden metastasis. Akhir sekali, kami mendapati wanita yang lebih tua cenderung memiliki jumlah sel CD4+CD25+Treg yang tinggi dalam Treg jika dibandingkan dengan pesakit lebih muda usianya. Jumlah sel CD4+CD25+Treg yang banyak mengimplikasi prognosis yang lemah dalam kalangan wanita susut haid. Kami mencadangkan bahawa Treg tersebut menyumbang kepada mekanisma di mana sel kanser terbebas daripada sistem imun.

ACKNOWLEDGEMENTS

I would like to express my deepest gratitude to my supervisor, Prof. Dr. Seow Heng Fong, for her generous guidance and endless support, encouragement and trust throughout the period of this project. Her careful reviews and constructive criticism have been crucial to fine-tune the project and also for the writing of the thesis. I am also thankful to her for giving me a chance to explore and work on this interesting project.

Special thanks also go to my co-supervisor, Dr Hairuszah Ithnin, for her guidance and support throughout the project. Her kindness in teaching me about the scoring and interpreting of the immunohistochemistry data is very much appreciated.

I also would like to thank Assoc. Prof. Dr Rohaizak Mohammad and Dr Naqiyah Ibrahim from Hospital Universiti Kebangsaan Malaysia for their help in collecting the breast cancer specimens and for providing the patient data. Without the specimens, I would not have been able to proceed with this project. Special thanks also go to Prof. Dr Cheong Soon Keng and Assoc. Prof. Dr Rohaizak Mohammad for their assistance in obtaining the approval from the HUKM ethics committee for this project.

I would like to express my gratitude to Prof. Dr William C Davis from Washington State University for his guidance in the interpretation of the flow cytometry data. I also like to express my appreciation to Dr Maha Abdullah from Universiti Putra Malaysia for teaching me the techniques required for running the flow cytometer.

Many thanks also go to Dr Ke Chen Ban for guiding me through the immunohistochemistry techniques.

To all my fellow lab mates, Ong Hooi Tin, Khor Tin Oo, Cheah Hwen-Yee, Janet Loh, Lim Pei Ching, Masriana Hassan, See Hui Shien, Yip Wai Kien, Choo Chee Wei, Leslie Than, Jee Jap Meng, Mahathir, in the Laboratory of Molecular Immunology, Faculty of Medicine and Health Science, Universiti Putra Malaysia, Anthonysamy, Siti Aishah, Siti Hasrizan and all the sales and technical personnels from the private sectors, thank you for your help and good luck.

Acknowledgement also goes to the Ministry of Sciences, Technology and Environment (MOSTE), Malaysia for providing financial support through the National Science Fellowship (NSF) programme as well as the IRPA prioritized research programme.

Last but not least, I would like to express my heartiest appreciation and thanks to my family members especially my mother and my husband. Thanks for your understanding and support throughout my studies.



TABLE OF CONTENTS

	Page
DEDICATION	ii
ABSTRACT	iii
ABSTRAK	vi
ACKNOWLEDGEMENT	ix
APPROVAL	xi
DECLARATION	xiii
LIST OF TABLE	xviii
LIST OF FIGURE	xx
LIST OF ABBREVIATION	xxii
 CHAPTER	
1. INTRODUCTION	1
2. LITERATURE REVIEW	
2.1 An Overview of Breast Cancer Biology	4
2.1.1 Epidemiology	4
2.1.2 Aetiology	5
2.1.3 Tumorigenesis	6
2.1.4 Physiology	9
2.1.5 Screening and Diagnosis	10
2.1.6 Treatment of Breast Cancer	10
2.2 Cancer Immunosurveillance	13
2.3 Mechanisms of Tumour Escape	16
2.3.1 Decreased or Loss of Tumour Antigens	17
2.3.2 Defective MHC class I Presentation Pathway	19
2.3.3 Dysfunction of Tumour Infiltrating Lymphocytes (TILs)	20
2.3.4 Immunosuppressor Factors	21
2.3.5 Non-Classical MHC Molecule	22
2.3.6 Regulatory T Lymphocytes (Treg)	22
2.3.7 Defective Mechanisms of Cell Death	24
2.3.8 Apoptosis of Activated Lymphocytes	25
2.4 Cancer Immunotherapy	26
2.4.1 Peptide – Based Vaccine	28
2.4.1.1 Effector cells	29
2.4.1.2 Tumour-Associated Antigen (TAA) Peptides	31
2.4.1.3 Antigen Presentation	33
2.4.1.4 Cytokines and Specific Antibodies to The Co-Stimulatory Molecule of CD8+	35
2.4.1.5 T Cell Proliferation	38
2.4.2 General Cytotoxic Mechanisms	39
2.4.2.1 Granule Mediated Cytolytic	40
2.4.2.2 Death-Receptor Cytotoxic Pathway	41
2.5 Tumour-Associated Antigens	43
2.5.1 Her2/neu	44
2.5.2 MAGE-1	46
2.5.3 MUC-1	47

2.5.4 Survivin	49
3. MATERIALS AND METHODS	52
3.1 Collection of Sample and Selection Criteria	52
3.2 Immunohistochemical Staining	53
3.2.1 Preparation of The Parrafin Embedded Block	53
3.2.2 Tissue Sectioning	53
3.2.3 Standard Immunohistochemistry Staining	54
3.2.3.1 Immunohistochemical Staining of MUC-1	55
3.2.3.2 Immunohistochemical Staining of MAGE-1	55
3.2.3.3 Immunohistochemistry Staining of Survivin	55
3.2.3.4 Scoring of the Staining	56
3.3 Cell Culture	56
3.3.1 Maintenance and Subculture of MCF-7 Cell Line	56
3.3.2 Cryopreservation	57
3.3.3 Trypan Blue Exclusion Test	57
3.4 HLA-A Typing	58
3.4.1 DNA Extraction From Whole Blood	58
3.4.2 Polymerase Chain Reaction	59
3.4.3 Agarose Gel Electrophoresis	60
3.4.4 Analysis of The Results	60
3.5 T Cell Stimulation	57
3.5.1 Peripheral Blood Mononuclear Cells (PBMCs)	61
Isolation	
3.5.2 Lymphocyte Culture	62
3.5.2.1 Optimization of Stimulation of Peripheral Blood Mononuclear Cells (PBMCs) From Normal Blood Donor	62
3.5.2.2 Stimulation of PBMCs From Patients With Infiltrating Ductal Carcinoma (IDC) of The Breast	63
3.5.3 Intracellular Interferon Gamma (IFN- γ) Staining	63
3.5.4 Fluorescence-Based Cell Mediated Cytotoxicity Assay	64
3.6 Immunophenotyping of Tumour Infiltrating Lymphocytes (TILs)	65
3.6.1 Enzymatic Digestion of Tumour Cells	65
3.6.2 Cell Fixation and Permeabilization	65
3.6.3 Cell Surface Staining	66
3.6.4 Flow Cytometric Analysis	67
3.7 Statistical Analysis	67
4. IMMUNOHISTOCHEMICAL STUDY OF TUMOUR-ASSOCIATED ANTIGENS IN INFILTRATING DUCTAL CARCINOMA OF THE BREAST	68
4.1 Introduction	68
4.2 Patient Data	68
4.2.1 Analysis of Patient Data	68
4.2.2 Discussion	69
4.3 Immunohistochemistry of MUC-1, MAGE-1 and Survivin	71

in Tumour Tissues From Infiltrating Ductal Carcinoma (IDC) of The Breast	
4.3.1 Immunoreactivity of MUC-1	71
4.3.2 Immunoreactivity of MAGE-1	76
4.3.3 Immunoreactivity of Survivin	78
4.3.4 Discussion	81
4.4 Correlation Between The Expression of MUC-1, MAGE-1 and Survivin and Clinicopathological Data	84
4.4.1 Results	84
4.4.2 Discussion	88
4.5 Conclusion	90
5. PEPTIDE-BASED CYTOTOXIC T LYMPHOCYTES PROLIFERATION ASSAY	92
5.1 Introduction	92
5.2 HLA-A Low Resolution Typing By Using SSP-PCR Method	93
5.2.1 Results	93
5.2.2 Discussion	94
5.3 Optimization of T cell Stimulation Condition Using Peripheral Blood Mononuclear Cells (PBMCs) From Normal Blood Donor	97
5.3.1 Results	97
5.3.2 Discussion	101
5.4 T Cell Stimulation Using Peripheral Blood Mononuclear Cells From Cancer Patient	103
5.4.1 Results	103
5.4.2 Discussion	107
5.5 Calcein-AM Cytotoxicity Assay	108
5.5.1 Results	108
5.5.2 Discussion	114
5.6 Conclusion	115
6. PHENOTYPE ANALYSIS OF TUMOUR INFILTRATING LYMPHOCYTES IN INFILTRATING DUCTAL CARCINOMAS OF THE BREAST	116
6.1 Introduction	116
6.2 Patient Data	117
6.2.1 Results	117
6.2.2 Discussion	121
6.3 Distribution of Lymphocyte Subsets Among Tumour Infiltrating Lymphocytes In Breast Cancer	122
6.3.1 Results	122
6.3.2 Discussion	133
6.4 Conclusion	137
7. GENERAL DISCUSSION	139
8. CONCLUSION AND FUTURE RECOMMENDATIONS	143
8.1 Conclusions	143



8.2 Future Recommendations	145
REFERENCES	146
APPENDICES	167
BIODATA OF THE AUTHOR	183

LIST OF TABLE

Table		Page
2.1	List of TAA peptides that are now undergone clinical trials in various parts of the world	32
4.1	Number of cases and correlation matrices among the clinicopathological factors (n= 49)	70
4.2	Detection of positive immunoreactivity for MUC-1, MAGE-1 and survivin in infiltrating ductal carcinoma (IDC) of the breast (n= 49)	75
4.3	Score of immunoreactivity of MUC-1 expression in the cytoplasm and at the plasma membrane, MAGE-1 and survivin in infiltrating ductal carcinoma (IDC) of the breast (n=49)	75
4.4	Correlation matrices between MUC-1 membrane, MUC-1 cytoplasm, MAGE-1 and survivin immunoreactivity in tumour tissues only in infiltrating ductal carcinoma (IDC) of the breast (n=49)	86
4.5	Correlation matrices between MUC-1, MUC-1 cytoplasm, MAGE-1 and survivin immunoreactivity and various clinicopathological factors in infiltrating ductal carcinoma (IDC) of the breast (n=49)	87
5.1	Functional analysis of stimulated PBMC from normal blood donor	99
5.2	Functional analysis of specific peptide stimulated PBMC from breast cancer patients (n=9)	106
5.3	The cytotoxic effect of Her2/neu (H2) or survivin (S2) peptide stimulated T cells on the target breast adenomacarcaroma cell line, MCF-7	112
6.1	Summary of number of cases that related to various clinicopathological factors (n=47)	119
6.2	Correlation Matrix among the clinicopathologic factors in infiltrating ductal carcinoma (IDC) of breast (n=47)	120
6.3	Distribution of different lymphocyte subsets among tumour infiltrating lymphocyte in infiltrating ductal carcinoma (IDC) of breast (n=47)	126

6.4	Correlation matrices among the distribution of different tumour infiltrating lymphocytes (TILs) subsets in infiltrating ductal carcinoma of breast. (n= 47)	131
6.5	Correlation Matrices of the distribution of different tumour infiltrating lymphocytes subsets and clinicopathologic factors in infiltrating ductal carcinoma of breast (n=47)	132
A.1	Primary antibodies, secondary antibodies, isotype controls and universal link used in the experiments	169
A.2	Peptides used in the T cells proliferation experiments	170
A.3	Biological response modifiers (recombinant protein and antibodies) used in the T cells proliferation experiments	170
C.1	Summary of clinical data, and phenotypic analysis of the tumour infiltrating lymphocytes (TILs) (n= 47) in sample from infiltrating ductal carcinoma (IDC) of the breast	173
C.2	Summary of clinical data, score of MUC-1 (both membrane and cytoplasm), MAGE-1 and survivin staining in tumour tissues (n=49) and apparently normal surrounding tissues (n=13) from infiltrating ductal carcinoma (IDC) of the breast	175
D.1	Frequency of HLA-A subtypes in patient of infiltrating ductal carcinoma (IDC) of the breast (n=40) and normal blood donors (n=13)	177

LIST OF FIGURE

Figure		Page
2.1	Cross section of the normal human breast	7
2.2	The three Es of immunoediting	14
2.3	The classical pathway for MHC class I antigen processing and presentation	34
3.1	Hemacytometer grids on the counting chamber of a hemacytometer	58
3.2	The appearance of cell interfaces before and after ficoll-hypaque separation of the diluted blood	57
4.1(a)- (g)	Localization of MUC-1 proteins in infiltrating ductal carcinoma (IDC) in various staining intensities	72-73
4.2	Immunoreactivity of cytoplasmic MUC-1 in 49 infiltrating ductal carcinoma breast tissues and 13 apparently normal surrounding tissues	74
4.3	Immunoreactivity of membrane-associated MUC-1 in 49 infiltrating ductal carcinoma breast tissues and 13 apparently normal surrounding tissues	74
4.4	Localization of MAGE-1 proteins at the cytoplasmic compartment of breast cancer cells in various staining intensities	77
4.5	Immunoreactivity of MAGE-1 in 49 infiltrating ductal carcinoma breast tissues and 13 apparently normal adjacent tissues	78
4.6	Localization of survivin proteins in cytoplasm of the breast cancer cells at various staining intensities	80
4.7	Immunoreactivity of survivin in 49 infiltrating ductal carcinoma breast tissues and 13 apparently normal adjacent tissues	81
5.1	Agarose gel electrophoresis showed some examples of reaction patterns for different HLA-A subtype from PCR for HLA-A typing	96
5.2	The expression frequency of different HLA-A types from blood of patients with infiltrating ductal carcinoma (IDC) (n= 40)	97

5.3	The relative staining intensity of CD69 and IFN- γ in different culture systems	93
5.4	Specific retention of calcein-AM in target cells but not in the effector cells	110
5.5	Retention of calcein-AM target MCF-7 breast cancer cells after co-culture with effector cells at different E/T ratio	111
5.6	Percentage of propidium iodide (PI) or ethidium bromide homodimer (EthD) in the co-culture system	113
6.1	A representative scatter plot to show the gating of various cell populations in the tumour suspension	127
6.2a-h	Phenotypic analysis of tumour infiltrating lymphocytes	128-129
6.3	The relative fluorescence intensity and percentage of positivity of different surface marker expression with respective to isotype control (in blue) on tumour infiltrating lymphocytes (TILs) of infiltrating ductal carcinoma (IDC) of the breast	130

LIST OF ABBREVIATIONS

α	alpha
β	beta
γ	gamma
δ	delta
%	percentage
°C	Degree of Celsius
μg	microgram
ACD	acid citrate dextrose
AICD	activated-induced cell death
AMC	atypical medullary carcinoma
APC	allophycocyanin
APCs	antigen presenting cells
APES	aminoproeyltrimethoxysilane
BCG	bacilli Calmette-Guerrin
BCS	breast conservation surgery
bp	base pair
BRAC	breast cancer susceptibility protein
BSA	bovine serum albumin
Calcein-AM	calcein- acetoxyethyl
CD	cluster of differentiation
cm	centimeter
CO ₂	carbon dioxide
COX-2	cyclooxygenase-2
CTLs	cytotoxic T lymphocytes
Cy-chrome	cyanine-chrome
DAB	diaminobenzidine tetrahydrochloride
DCIS	ductal carcinoma in situ
DCs	dendritic cells
DMSO	dimethylsulphoxide
DNA	deoxyribonuclease acid
DTH	delayed type hypersensitivity
EGFR	epithelial growth factor receptor
ELISA	enzyme-linked immunosorbent assay
ER	oestrogen receptor
E/T	effector/target ratio
EthD	ethidium bromide homodimer
FADD	Fas-associated protein with death domain
FASL	Fas ligand
FBS	fetal bovine serum
Fc	forward scatter
FITC	fluorescein isothiocyanate
FL	filter
FLICE	FADD homologous Interleukine-1 beta converting enzyme/ <i>Caenorhabditis elegans</i> cell-death protein 3- like protease
FOXP	Foxhead/ winged-helix
GITR	glucocorticoid induced tumour necrosis receptor

GSK	glycogen synthase kinase
Her2/neu	human epidermal growth factor 2/ neu
HLA	human leukocyte antigen
HPV	human papillomavirus
HRT	hormone replacement therapy
HUKM	Hospital Universiti Kebangsaan Malaysia
IAP	inhibitory of apoptosis
ICAM-1	intracellular cell adhesion molecules-1
IDC	infiltrating ductal carcinoma
IFN-γ	interferon gamma
IL-	interleukin
iNKRs	inhibitory NK receptor
LAK	lymphocyte activated killer
LMP	latent membrane protein
LOH	loss of heterozygosity
MAGE	melanoma-associated antigen
MAPK	mitogen-activated protein kinase
MART-1	melanoma antigen recognized by T cell-1
MC	medullary carcinoma
MECL-1	multicatalytic endopeptidase complex like-1
MHC	major histocompatibility complex
ml	milliliter
mm	millimeter
MUC	mucin
NCCN	National Comprehensive Cancer Network
NKT	natural killer T
NSABP P1	National Surgical Adjuvant Breast and Bowel project –Phase 1
PBMCs	peripheral blood mononuclear cells
PBS	phosphate buffered saline
PCR-SSP	polymerase chain reaction- sequence specific primer
PGE ₂	prostaglandin E2
PE	phycoeythrin
PerCp	peridinin chlorophyll protein
PI	propidium iodide
PI3K-Akt	phosphatidylinositol 3- kinase/ Akt
PR	progesterone receptor
rIL-	recombinant interleukin
RNAi	interference ribosomal nucleic acid
RPMI 1640	Roswell Park Memorial Institute 1640
TAAs	tumour-associated antigens
TAE	Tris-acetate-EDTA
TAP	transporter associated with antigen processing
TCR	T cell receptor
TGF	transforming growth factor
Th	T helper
TILs	tumour infiltrating lymphocytes
TLR	toll-like receptor
TMC	typical medullary carcinoma
TNFR	tumour necrosis factor receptor
TRAIL	tumour necrosis factor receptor- related apoptosis inducing ligand

Treg	regulatory T lymphocyte
U	international unit
VEGF	vascular endothelial growth factor
VNTR	variable number of tandem repeats